Organon & Co (LSE:0A9W)
$ 15.89 0.11 (0.7%) Market Cap: 4.07 Bil Enterprise Value: 12.06 Bil PE Ratio: 3.14 PB Ratio: 8.27 GF Score: 67/100
Back to the Transcripts List

Q2 2024 Organon & Co Earnings Call Transcript

Aug 06, 2024 / 12:30PM GMT
Release Date Price: $18.52

Key Points

Positve
  • Revenue for Q2 2024 was $1.6 billion, representing a 2% growth rate at constant currency.
  • The biosimilars franchise grew 22%, showing strong performance.
  • Adjusted EBITDA was $513 million, representing a 31.9% adjusted EBITDA margin.
  • NEXPLANON showed significant growth, up 13% ex-FX in the second quarter.
  • The company is on track to deliver its third consecutive year of constant currency revenue growth.
Negative
  • The established brands franchise was down 1% in Q2 2024.
  • Global fertility business declined by 8% ex-FX in the second quarter.
  • Adjusted gross margin decreased to 62% from 62.9% in the same quarter last year.
  • Year-to-date non-GAAP adjusted net income decreased to $289 million from $336 million in 2023.
  • China's revenue was down 4% ex-FX in the quarter, with slower-than-expected rollout of ART reimbursement.
Operator

Thank you for standing by. My name is Mandeep, and I'll be your operator today. At this time, I'd like to welcome everyone to the Organon Q2 2024 earnings call webcast. (Operator Instructions)

I would now like to turn the call over to Jennifer Halchak, Head of Investor Relations. You may begin.

Jennifer Halchak
Organon & Co - Head, Investor Relations

Thank you, operator. Good morning, everyone. Thank you for joining Organon's second-quarter 2024 earnings call. With me today are Kevin Ali, Organon's Chief Executive Officer; and Matt Walsh, our Chief Financial Officer. Also joining us for the Q&A portion of this call is Organon's Head of R&D, Juan Camilo Ariona Ferreira.

Today, we will be referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events & Presentations section of our Organon Investor Relations website at www.organon.com.

Before we

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.